Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients

Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients

Objectives. A phase I pretargeted radioimmunotherapy trial (EudractCT 200800603096) was designed in patients with metastatic lung cancer expressing carcinoembryonic antigen (CEA) to optimize bispecific antibody and labelled peptide doses, as well as the delay between their injections.Methods. Three...

Full description

Bibliographic Details
Main Authors: Caroline eBodet-Milin, Ludovic eFerrer, Aurore eRauscher, Damien eMasson, Latifa eRbah-Vidal, Alain eFaivre-Chauvet, Caroline eRousseau, Jose eHureaux, Olivier eCouturier, Pierre-Yves eSalaun, David M. Goldenberg, Robert eSharkey, Françoise eKraeber-Bodéré, Jacques eBarbet
Format: Article
Language:English
Published: Frontiers Media S.A. 2015-11-01
Series:Frontiers in Medicine
Subjects:
Radioimmunotherapy
lung cancer
pharmacokinetics
SPECT
SPECT/CT
Dosimetry
Online Access:http://journal.frontiersin.org/Journal/10.3389/fmed.2015.00084/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fmed.2015.00084/full

Similar Items